Ranbaxy facilities searched by FDA

Share this article:
Federal officials Wednesday conducted a search of the New Jersey offices and manufacturing facilities of Indian generic drugmaker Ranbaxy Laboratories. A company spokesman said in published reports that the action came as a surprise. “We’re not aware of any wrongdoing,” Ranbaxy spokesman Charles Caprariello said in a published report. “We’re cooperating and providing them with (material) even today.” Caprariello said officials from the FDA searched two Ranbaxy sites in New Jersey – a manufacturing plant in New Brunswick and administrative offices in Princeton. He declined to comment on whether the officials removed anything from the sites. “We’re working with the authorities to address the issues and hopefully resolve everything so we can get back to business as normal,” he said. Caprariello told The Wall Street Journal that the management team remains intact and employees are being informed about what has happened. Inquires to the FDA from news agencies about the searches were referred to the Justice Department. A Justice Department spokeswoman told the Associated Press, “We don’t comment on ongoing investigations.” Ranbaxy is based in Gurgaon, India and is that nation’s largest drug company. Last month, the company received approval to make a generic version of Pfizer’s blockbuster antidepressant Zoloft. Other generic drugmakers already had approval for generic versions.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.